healthandpharma7d
FDA Approves Innovative ADC Datroway for Unresectable or Metastatic HR+, HER2- Breast Cancer
The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...
healthandpharma10d
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer Patients
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
healthandpharma7d
FDA Approves Sotorasib and Panitumumab Combination: Doubling Survival for KRAS G12C-Mutated Colorectal Cancer
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
healthandpharma10d
The Internet of Medical Things needs a new security model to fulfil its potential
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...
healthandpharma9d
Regulatory Approval Boosts Pelareorep’s Innovative Oncolytic Virus Therapy for Pancreatic Cancer
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
healthandpharma10d
FDA Grants Priority Review to Datopotamab Deruxtecan for Advanced EGFR+ Lung Cancer
Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.